Orthofix International

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Orthofix and SeaSpine post mixed Q4 results, eye synergies and growth

SeaSpine and Orthofix reported mixed Q4 performances but demonstrated overall revenue growth for the full year, with positive revenue guidance for 2023.
The merger synergies and product demand strengths are key highlights, while challenges in profitability and regulatory hurdles in Europe require attention.
Opportunities lie in integration efforts, cost efficiencies, and exploring new markets, indicating a strategic growth trajectory for the combined entity.
The upcoming Analyst Teach-In event and focus on operational planning underscore the commitment to transparency and strategic alignment post-merger.

Orthofix reports robust Q1 earnings, raises full-year revenue guidance

Orthofix International's Q1 2023 earnings call highlighted strong financial performance, strategic initiatives, and raised revenue guidance, underscoring growth prospects.
The company's focus on operational efficiency, product categories, and profitability signals a resilient business strategy amidst market challenges and competitive landscape.
With a robust financial foundation, Orthofix is well-positioned to navigate challenges, capitalize on growth opportunities, and drive sustainable value creation for shareholders.

Orthofix International reports robust Q2 earnings and growth outlook

Orthofix International delivered a strong Q2 performance, with notable revenue growth and positive outlook for 2023.
Efforts to integrate merged businesses are yielding results, with a focus on revenue enhancement and operational streamlining.
Challenges such as cash flow and supply chain disruptions are being addressed through strategic investments and operational improvements.
The company's focus on growth, efficiency, and strategic partnerships positions it well for future success and value creation.

Orthofix reports robust Q3 revenue growth, eyes profitability and stability

Orthofix International demonstrated strong revenue growth and market performance in Q3 2023, driven by successful product lines and strategic initiatives.
While facing challenges such as cash flow outflows and margin adjustments, the company remains focused on profitability and financial stability.
Opportunities lie in sustaining positive momentum, achieving cash flow positivity in 2024, and leveraging growth prospects through product innovation and market expansion.

Orthofix reports robust Q4 earnings, eyes growth in key segments

Orthofix International's Q4 2023 earnings call highlighted strong financial performance, strategic initiatives, and growth in key segments.
The company's focus on market share, distributor relationships, and portfolio enhancements positions it well for future success.
Despite challenges in a competitive landscape, Orthofix remains optimistic about growth opportunities and aims for continued innovation and collaboration.

Orthofix International reports robust Q1 earnings and raises 2024 guidance

Orthofix International (OFIX) delivered a strong Q1 2024 performance, focusing on growth, innovation, and operational efficiency. The company showcased revenue growth, margin expansion, and strategic priorities for the year. Challenges include sustaining growth in competitive markets and optimizing operational aspects, while opportunities lie in leveraging technology and talent for further growth.

Orthofix International reports strong Q2 performance and outlines growth strategies

Orthofix International's Q2 performance reflects solid revenue growth and margin expansion, supported by new product releases and operational efficiency.
While facing challenges in cash flow optimization, the company's strategic focus on innovation and synergies positions it well for future growth.
Opportunities in technology investment, cross-selling, and distribution enhancements offer avenues for Orthofix International to drive sustained growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ATLANTA, Aug. 22, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Orthofix Medical Inc. (“Orthofix” or “the Company”) (NASDAQ: OFIX). The lawsuit alleges that Orthofix's management team was engaged in “repeated inappropriate and offensive conduct that violated multiple code of conduct requirements,” which was “inconsistent with the Company's values and culture.” When the truth about the Company's management team was revealed, the price of Orthofix common stock suffered sharp declines.

SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf Orthofix Medical Inc. (OFIX) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Orthofix Medical Inc. Is Being Investigated By The Schall Law Firm For Securities Fraud And Investors Are Invited To Join

NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Texas on behalf of all persons or entities who purchased or otherwise acquired Orthofix Medical, Inc. (“Orthofix” or the “Company”) (NASDAQ: OFIX) securities between October 11, 2022, and September 12, 2023, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company's investors under the federal securities laws.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Orthofix Medical, Inc. (OFIX)

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Orthofix Medical Inc. (“Orthofix” or the “Company”) (NASDAQ: OFIX) in the United States District Court for the Eastern District of Texas on behalf of all persons and entities who purchased or otherwise acquired Orthofix securities between October 11, 2022, and September 12, 2023, both dates inclusive (the “Class Period”). Investors have until October 21, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

ORTHOFIX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Orthofix Medical Inc. and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Eastern District of Texas against Orthofix Medical, Inc. (“Orthofix” or the “Company”) (NASDAQ: OFIX), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a) of the Securiti.

Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Orthofix Medical, Inc. (NASDAQ: OFIX)

LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Inquiring Into Orthofix Medical Inc.'s Possible Securities Law Violations And Wants Shareholder Involvement

LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Orthofix Medical Inc. For potential Securities Law Violations And Seeks Investors To Participate

ATLANTA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Orthofix Medical Inc. (“Orthofix” or “the Company”) (NASDAQ: OFIX) complied with federal securities laws. On September 12, 2023, Orthofix announced it had terminated three executives in the Company for cause, following an investigation conducted by independent counsel. The Company stated that “the Board determined that each of these executives engaged in repeated inappropriate and offensive conduct that violated multiple code of conduct requirements and was inconsistent with the Company's values and culture.” Following this news, the price of the Company's stock dropped.

SHAREHOLDER ALERT: Investigation of Orthofix Medical Inc. (OFIX) Announced by Holzer & Holzer, LLC

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Inquiring Into Orthofix Medical Inc. For Possible Securities Law Violations And Wants Investors To Join

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Orthofix Medical Inc. And Seeks Affected Investors To Participate

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Potential Violations By Orthofix Medical Inc. And Invites Shareholders To Participate

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Violations By Orthofix Medical Inc. And Encourages Shareholders To Participate

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Violations By Orthofix Medical Inc. And Urges Investors To Participate

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Orthofix Medical Inc. And Urges Affected Investors To Engage In The Discussion

LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Orthofix Medical Inc And Encourages Affected Investors To Participate In The Discussion

LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Conducting An Investigation Into Orthofix Medical Inc. and Encourages Affected Investors To Join The Conversation

LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Orthofix Medical Inc And Urges Impacted Investors To Participate In The Discussion

LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Probing Orthofix Medical Inc And Encourages Affected Investors To Join The Conversation

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Investigates Orthofix Medical Inc And Urges Affected Investors To Join The Conversation

Orthofix Medical Inc. (NASDAQ:OFIX ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Julie Dewey - Chief IR and Communications Officer Massimo Calafiore - President and CEO Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Ryan Zimmerman - BTIG Jason Wittes - ROTH MKM Operator Thank you for standing by. My name is Krista and I will be your conference operator today.

Orthofix Medical Inc. (OFIX) Q2 2024 Earnings Call Transcript

Orthofix (OFIX) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to earnings of $0.02 per share a year ago.

Orthofix (OFIX) Surpasses Q2 Earnings and Revenue Estimates

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2024 and increased its full-year 2024 financial guidance. Recent Highlights Second quarter 2024 net sales of $198.6 million, an increase of 6% on a reported and constant currency basis compared to second quarter 2023 Bone Growth Therapies (BGT) net sales growth of 12% compared to second quarter 2023, marking six consecutive quarters with double-digit.

Orthofix Reports Second Quarter 2024 Results and Raises Full-Year 2024 Financial Guidance

Bicycle Therapeutics Plc - ADR

Bentley Systems

908 Devices

Mueller Industries

New Jersey Resources

D-Wave Quantum Inc

Summit Therapeutics

Zoetis

SALT LAKE CITY--(BUSINESS WIRE)--As regulatory deadlines approach, 25 snack food suppliers align with ReposiTrak for its state-of-the-art, hardware-free traceability solutions.

25 Snack Food Suppliers Queue Up for ReposiTrak's Rapidly Expanding Food Traceability Network

LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Orthofix Medical Inc And Encourages Affected Investors To Join The Conversation

LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Orthofix International Stock (OFIX)